Director Kim R. Tsuchimoto of Monopar Therapeutics filed a Form 4 on November 4, 2026, disclosing a series of stock option exercises and open-market sales of common stock executed on November 2 and November 4, 2026, pursuant to a Rule 10b5-1 plan.

Key Highlights

  • 10b5-1 Plan: All transactions were made pursuant to a Rule 10b5-1 plan executed by Tsuchimoto on May 27, 2026.
  • Options exercised: A total of 4,090 shares were acquired via option exercises across both transaction dates, at exercise prices of $30 and $14 per share.
  • Shares sold: A total of 4,090 shares of common stock were sold across five sale transactions on November 2 and November 4, 2026, at weighted average prices ranging from $70.10 to $72.21 per share.
  • Direct holdings reduced to zero: Following all reported transactions, Tsuchimoto's directly held shares of common stock stand at 0.
  • Indirect holdings remain: Tsuchimoto retains indirect beneficial ownership of 11,486 shares held by the Kim R. Tsuchimoto Trust dated October 6, 2015.
  • Remaining options: After the exercises, Tsuchimoto holds 4,110 stock options at $30 (expiring August 27, 2028) and 6,105 stock options at $14 (expiring June 30, 2029) on a direct basis.

Tsuchimoto's Option Exercises and Share Sales at Monopar Therapeutics

According to the filing, director Kim R. Tsuchimoto exercised stock options and sold the resulting shares of Monopar Therapeutics (NASDAQ:MNPR) common stock on two dates. On November 2, 2026, Tsuchimoto exercised 1,199 stock options at $30 per share, acquiring 1,199 shares, and then sold all 1,199 shares at a weighted average price of $70.10, with individual sale prices ranging from $70.00 to $70.27 per share, leaving zero directly held shares after that date's transactions.

On November 4, 2026, the filing reports three additional option exercises: 856 shares acquired at $30 per share and 2,035 shares acquired at $14 per share, together bringing the direct position to 2,891 shares before the day's sales. Those shares were then sold in three separate transactions: 1,295 shares at a weighted average of $70.75 (ranging from $70.13 to $71.098), 996 shares at a weighted average of $71.35 (ranging from $71.14 to $71.58), and 600 shares at $72.21 per share, reducing the direct balance to zero. The filing notes that the $30 options originated from an August 28, 2018 grant of up to 8,220 shares, and the $14 options from a February 2, 2022 grant of up to 16,280 shares, with 6,105 of the latter forfeited upon Tsuchimoto's retirement from the company on July 1, 2024.

All transactions were carried out under the Rule 10b5-1 plan Tsuchimoto established on May 27, 2026, as stated in the filing. The form was signed by Quan Vu as attorney-in-fact on November 4, 2026. The reporting person is identified as a director of Monopar Therapeutics Inc.

What Was Disclosed

The filing reports option exercises totaling 4,090 shares and corresponding sales of 4,090 shares by director Kim R. Tsuchimoto between November 2 and November 4, 2026, executed under a 10b5-1 plan, leaving zero directly held shares and 11,486 shares held indirectly through a trust.